From the Hôpital Cardiologique du Haut Lévêque, Université Victor-Segalen Bordeaux, Pessac, France (D.S., P.K., S.M., V.A.-L., P.P., S.B.W., K.R., Y.K., L.R., A.J., N.L., M.P., M.D., M.O'N., S.K., R.W., T.R., H.C., A.J.S., S.Y., A.D., N.D., M.H., F.S., M.H., P.J.); and Division of Cardiology, Department of Medicine, Medical University of Graz, Austria (D.S., M.M.).
Circ Arrhythm Electrophysiol. 2015 Feb;8(1):18-24. doi: 10.1161/CIRCEP.114.001943. Epub 2014 Dec 20.
This study aimed to determine 5-year efficacy of catheter ablation for persistent atrial fibrillation (AF) using AF termination as a procedural end point.
One hundred fifty patients (57±10 years) underwent persistent AF ablation using a stepwise ablation approach (pulmonary vein isolation, electrogram-guided, and linear ablation) with the desired procedural end point being AF termination. Repeat ablation was performed for recurrent AF or atrial tachycardia. AF was terminated by ablation in 120 patients (80%). Arrhythmia-free survival rates after a single procedure were 35.3%±3.9%, 28.0%±3.7%, and 16.8%±3.2% at 1, 2, and 5 years, respectively. Arrhythmia-free survival rates after the last procedure (mean 2.1±1.0 procedures) were 89.7%±2.5%, 79.8%±3.4%, and 62.9%±4.5%, at 1, 2, and 5 years, respectively. During a median follow-up of 58 (interquartile range, 43-73) months after the last ablation procedure, 97 of 150 (64.7%) patients remained in sinus rhythm without antiarrhythmic drugs. Another 14 (9.3%) patients maintained sinus rhythm after reinitiation of antiarrhythmic drugs, and an additional 15 (10.0%) patients regressed to paroxysmal recurrences only. Failure to terminate AF during the index procedure (hazard ratio 3.831; 95% confidence interval, 2.070-7.143; P<0.001), left atrial diameter≥50 mm (hazard ratio 2.083; 95% confidence interval, 1.078-4.016; P=0.03), continuous AF duration≥18 months (hazard ratio 1.984; 95% confidence interval, 1.024-3.846; P<0.04), and structural heart disease (hazard ratio 1.874; 95% confidence interval, 1.037-3.388; P=0.04) predicted arrhythmia recurrence.
In patients with persistent AF, an ablation strategy aiming at AF termination is associated with freedom from arrhythmia recurrence in the majority of patients over a 5-year follow-up period. Procedural AF nontermination and specific baseline factors predict long-term outcome after ablation.
本研究旨在确定以房颤终止作为终点的导管消融术治疗持续性房颤的 5 年疗效。
150 例患者(57±10 岁)采用逐步消融方法(肺静脉隔离、电描记图指导和线性消融)进行持续性房颤消融,期望的终点是房颤终止。对于复发性房颤或房性心动过速,再次进行消融。在 120 例患者(80%)中,通过消融使房颤终止。单次消融后无心律失常生存率分别为 35.3%±3.9%、28.0%±3.7%和 16.8%±3.2%,1、2 和 5 年时分别为 35.3%±3.9%、28.0%±3.7%和 16.8%±3.2%。最后一次消融后(平均 2.1±1.0 次)无心律失常生存率分别为 89.7%±2.5%、79.8%±3.4%和 62.9%±4.5%,1、2 和 5 年时分别为 89.7%±2.5%、79.8%±3.4%和 62.9%±4.5%。在最后一次消融后中位随访 58(四分位距,43-73)个月期间,150 例患者中有 97 例(64.7%)在不服用抗心律失常药物的情况下仍保持窦性心律。另外 14 例(9.3%)患者在重新开始服用抗心律失常药物后仍保持窦性心律,还有 15 例(10.0%)患者仅转为阵发性复发。指数手术期间未能终止房颤(风险比 3.831;95%置信区间,2.070-7.143;P<0.001)、左心房直径≥50mm(风险比 2.083;95%置信区间,1.078-4.016;P=0.03)、持续房颤时间≥18 个月(风险比 1.984;95%置信区间,1.024-3.846;P<0.04)和结构性心脏病(风险比 1.874;95%置信区间,1.037-3.388;P=0.04)均预测心律失常复发。
在持续性房颤患者中,以房颤终止为目标的消融策略与大多数患者在 5 年随访期间的无心律失常复发相关。手术中房颤未终止和特定的基线因素可预测消融后的长期结果。